Unknown

Dataset Information

0

A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2.

ABSTRACT: Inoculation against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is ongoing worldwide. However, the emergence of SARS-CoV-2 variants could cause immune evasion. We developed a bivalent nanoparticle vaccine that displays the receptor binding domains (RBDs) of the D614G and B.1.351 strains. With a prime-boost or a single-dose strategy, this vaccine elicits a robust neutralizing antibody and full protection against infection with the authentic D614G or B.1.351 strain in human angiotensin-converting enzyme 2 transgene mice. Interestingly, 8 months after inoculation with the D614G-specific vaccine, a new boost with this bivalent vaccine potently elicits cross-neutralizing antibodies for SARS-CoV-2 variants in rhesus macaques. We suggest that the D614G/B.1.351 bivalent vaccine could be used as an initial single dose or a sequential enforcement dose to prevent infection with SARS-CoV-2 and its variants.

SUBMITTER: Yuan Y 

PROVIDER: S-EPMC8695190 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Inoculation against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is ongoing worldwide. However, the emergence of SARS-CoV-2 variants could cause immune evasion. We developed a bivalent nanoparticle vaccine that displays the receptor binding domains (RBDs) of the D614G and B.1.351 strains. With a prime-boost or a single-dose strategy, this vaccine elicits a robust neutralizing antibody and full protection against infection with the authentic D614G or B.1.351 strain in human angiot  ...[more]

Similar Datasets

Unknown SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern.
| S-EPMC10244545 | biostudies-literature
Unknown Bivalent mRNA vaccine effectiveness against SARS-CoV-2 variants of concern.
| S-EPMC10304269 | biostudies-literature
Unknown Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants.
| S-EPMC9972327 | biostudies-literature
Unknown A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross-Protection Activity against Multiple SARS-CoV-2 Sublineages.
| S-EPMC10520630 | biostudies-literature
Unknown A potent, broadly protective vaccine against SARS-CoV-2 variants of concern.
| S-EPMC9653380 | biostudies-literature
Unknown Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron.
| S-EPMC9334538 | biostudies-literature
Unknown Effectiveness of a broad-spectrum bivalent mRNA vaccine against SARS-CoV-2 variants in preclinical studies.
| S-EPMC10906132 | biostudies-literature
Unknown Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants.
| S-EPMC9693459 | biostudies-literature
Unknown Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants.
| S-EPMC9106700 | biostudies-literature
Unknown Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models.
| S-EPMC10796936 | biostudies-literature